MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management ...

-- Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic (GTC) seizures -- NeuroPace, ...

NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today announced favorable Medicare reimbursement updates for the RNS ® ...

NeuroPace, a medical device company specializing in epilepsy treatments, was hit with an employment discrimination lawsuit on Nov. 20 in California Superior Court for Santa Clara County. The action, ...

MOUNTAIN VIEW, Calif. (AP) — MOUNTAIN VIEW, Calif. (AP) — NeuroPace Inc. (NPCE) on Tuesday reported a loss of $3.5 million in its third quarter. The Mountain View, California-based company said it had ...

Reserve Bank of Australia Governor Michele Bullock highlighted four key areas of focus in work between policymakers, the government and industry to modernize the nation’s payments system, while ...

MOUNTAIN VIEW, Calif. (AP) — MOUNTAIN VIEW, Calif. (AP) — NeuroPace Inc. (NPCE) on Tuesday reported a loss of $8.7 million in its second quarter. On a per-share basis, the Mountain View, ...

NeuroPace, Inc. (NASDAQ:NPCE) is among the best NASDAQ stocks under $50 to buy. Cantor Fitzgerald reiterated its Overweight rating on NeuroPace, Inc. (NASDAQ:NPCE), with a price target of $16.00, ...

MOUNTAIN VIEW, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that ...

Shares of NeuroPace (NASDAQ:NPCE) shed ~24% in the premarket on Tuesday after the MedTech said that its NAUTILUS study evaluating its neuromodulation therapy RNS System failed to reach the primary ...

-- NeuroPace (NPCE) has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- ...